A placebo controlled study evaluating the effectivess of medication in preventing Seasonal Affective Disorder

Condition	Treatment or Intervention	Phase
Seasonal Affective Disorder	Drug: Investigational Seasonal Affective Depression Drug	Phase III

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion

• Patient has a history of Major Depressive Disorder (MDD) with a seasonal pattern.

Exclusion

• Patient has a current or past history of seizure disorder or brain injury.
• Patient has a history or current diagnosis of anorexia nervousa or bulimia.
• Patient has recurrent summer depression more frequently than winter depression.
• Patient has primary diagnosis of panic disorder, Obsessive Compulsive Disorder (OCD), Posttraumatic Stress Disorder.(PTSD), acute distress disorder, bipolar II disorder or other psychotic disorders.
• Patient has initiated psychotherapy within the last 3 months.

Alaska
      Anchorage,  Alaska,  99508,  United States
Connecticut
      Hamden,  Connecticut,  06518,  United States
Delaware
      Newark,  Delaware,  19713,  United States
      Wilmington,  Delaware,  19808,  United States
District of Columbia
      Washington,  District of Columbia,  20016,  United States
Idaho
      Boise,  Idaho,  83702,  United States
Illinois
      Northfield,  Illinois,  60093,  United States
      Elgin,  Illinois,  60123,  United States
      Oakbrook Terrace,  Illinois,  60181,  United States
      Hoffman Estates,  Illinois,  60194,  United States
      Edwardsville,  Illinois,  62025,  United States
Iowa
      Cedar Rapids,  Iowa,  52401,  United States
Kansas
      Overland Park,  Kansas,  66211,  United States
Maryland
      Rockville,  Maryland,  20852,  United States
      Rockville,  Maryland,  20852,  United States
      Baltimore,  Maryland,  21204,  United States
Massachusetts
      Belmont,  Massachusetts,  02478,  United States
Michigan
      Farmington Hills,  Michigan,  48334,  United States
Minnesota
      Minneapolis,  Minnesota,  55454,  United States
Missouri
      St. Louis,  Missouri,  63108,  United States
Nebraska
      Omaha,  Nebraska,  68198,  United States
New Jersey
      Kenilworth,  New Jersey,  07033,  United States
      Moorestown,  New Jersey,  08057,  United States
      Princeton,  New Jersey,  08540,  United States
      Piscataway,  New Jersey,  08854,  United States
New York
      New York,  New York,  10021,  United States
      New York,  New York,  10032,  United States
      New York,  New York,  10128,  United States
      Lawrence,  New York,  11559,  United States
      Albany,  New York,  12208,  United States
      Rochester,  New York,  14618,  United States
Ohio
      Toledo,  Ohio,  43623,  United States
      Lyndhurst,  Ohio,  44124,  United States
      Cincinnati,  Ohio,  45219,  United States
Oregon
      Portland,  Oregon,  97201,  United States
      Portland,  Oregon,  97209,  United States
      Lake Oswego,  Oregon,  97210,  United States
      Eugene,  Oregon,  97401,  United States
Pennsylvania
      Allentown,  Pennsylvania,  18104,  United States
      Havertown,  Pennsylvania,  19083,  United States
      Philadelphia,  Pennsylvania,  19106,  United States
Rhode Island
      Lincoln,  Rhode Island,  02865,  United States
Vermont
      Woodstock,  Vermont,  05091,  United States
Washington
      Spokane,  Washington,  99204,  United States
Wisconsin
      Menomonee Falls,  Wisconsin,  53051,  United States
      Brown Deer,  Wisconsin,  53223,  United States
      Middleton,  Wisconsin,  53562,  United States
      Madison,  Wisconsin,  53719,  United States

Study ID Numbers:  100006
Record last reviewed:  July 2004
Last Updated:  October 13, 2004
Record first received:  September 25, 2003
ClinicalTrials.gov Identifier:  NCT00069459
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08